Alnylam Pharmaceuticals (ALNY) vs. IONS and ARWR: Can Pipeline Growth Restore Confidence After the Guidance Cut?
Is ALNY a good stock to buy? We came across a bullish thesis on Alnylam Pharmaceuticals, Inc. on Astute Optics – US’s ...
Model output · Signal date 2026-10-16
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Rating · 90D
Alpha
90-day forecast
Sign up free to reveal
30-day forecast
Alpha
Rank in coverage
Middle 30%
of 5172 stocks scored
Rank correlation · 90D
56.0%
Spearman, 357 dates
Market Cap
$31.02B
large-cap · #19 of 60 peers
Summary
Alnylam Pharmaceuticals, Inc. (ALNY) stock forecast summary
On Oct. 16, 2026, ALNY is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5172 stocks scored that day.
Alnylam Pharmaceuticals, Inc. is a large-cap company with a market capitalization of $31.02B. It ranks number 19 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast.
For ALNY, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 56.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 32.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, ALNY included.
Follow ALNY freePrice
ALNY price chart and AI forecast
Cross-section · 2026-10-16
How ALNY ranks among 5172 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals · 2026-06-30
Alnylam Pharmaceuticals, Inc. (ALNY) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Pharmaceutical Preparations peers listed below that report each metric.
Valuation & Market
| Metric | ALNY | Rank |
|---|---|---|
| Market Cap | $31.02B | 19/60 |
| P/E Ratio | 58.25x | 9/32 |
| P/B Ratio | 22.91x | 6/42 |
| EPS | $3.98 | – |
| Book Value/Share | $10.12 | – |
Profitability & Margins
| Metric | ALNY | Rank |
|---|---|---|
| ROE | 39.6% | 7/38 |
| ROA | 9.6% | 12/43 |
| ROIC | 17.7% | 10/46 |
| Gross Margin | 79.5% | 20/35 |
| Operating Margin | 16.2% | 18/39 |
| Net Margin | 12.2% | 15/35 |
| EBT Margin | 12.3% | 24/46 |
| Tax Rate | 1.3% | – |
Financial Health
| Metric | ALNY | Rank |
|---|---|---|
| Current Ratio | 3.05x | 31/59 |
| Quick Ratio | 2.99x | 12/43 |
| D/E Ratio | 3.11x | 8/48 |
| Financial Leverage | 4.11x | 8/48 |
| Interest Coverage | 1.9x | 16/36 |
| Working Capital | $3.11B | 14/59 |
Cash Flow
| Metric | ALNY | Rank |
|---|---|---|
| Operating Cash Flow | $1.04B | 24/59 |
Operational Efficiency
| Metric | ALNY | Rank |
|---|---|---|
| Inventory Turnover | 9.3x | 2/35 |
| Days Inventory | 39 days | 34/35 |
| Payables Period | 44 days | 24/25 |
Income Statement
| Metric | ALNY | Rank |
|---|---|---|
| Operating Income | $715M | 18/51 |
| Net Income | $536M | 18/46 |
| R&D Expense | $1.47B | 18/58 |
| SG&A Expense | $1.32B | 21/40 |
| Cost of Goods Sold | $905M | 21/36 |
Dividend & Shareholder Information
| Metric | ALNY | Rank |
|---|---|---|
| Shares Outstanding | 134M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $4.62B | 83.1% of assets |
| Cash & Short-term Investments | $1.71B | 30.7% of assets |
| Accounts Receivable | $913M | 16.4% of assets |
| Inventory | $97M | 1.7% of assets |
| Total Liabilities | $4.20B | 75.6% of assets |
| Short-term Debt | $1.40B | 25.3% of assets |
Quarterly Financial Reports
ALNY quarterly financials and insider trading
Industry Peers · Pharmaceutical Preparations
Alnylam Pharmaceuticals, Inc. (ALNY) industry peers
Companies classified under the same SEC industry code as Alnylam Pharmaceuticals, Inc. (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| ALNY Alnylam Pharmaceuticals, Inc. | ▶ | $31.02B |
| LLY Eli Lilly & Co | ▶ | $1.18T |
| JNJ Johnson & Johnson | ▼ | $615.87B |
| ABBV Abbvie Inc. | ▶ | $504.37B |
| MRK Merck & Co., Inc. | ▲ | $360.08B |
| NVS Novartis Ag | ▼ | $287.41B |
| AZN Astrazeneca Plc | ▼ | $256.39B |
| ABT Abbott Laboratories | ▼ | $182.39B |
| NVO Novo Nordisk A S | ▼ | $172.56B |
| PFE Pfizer Inc | ▶ | $168.60B |
| VRTX Vertex Pharmaceuticals Inc / Ma | ▶ | $126.66B |
| BMY Bristol Myers Squibb Co | ▶ | $122.05B |
| GSK Gsk Plc | ▼ | $100.46B |
| SNY Sanofi | ▼ | $100.12B |
| REGN Regeneron Pharmaceuticals, Inc. | ▶ | $81.76B |
| TAK Takeda Pharmaceutical Co Ltd | ▼ | $61.45B |
| TEVA Teva Pharmaceutical Industries Ltd | ▼ | $48.36B |
| ONC Beone Medicines Ltd. | ▲ | $41.96B |
| ZTS Zoetis Inc. | ▼ | $32.80B |
| RPRX Royalty Pharma Plc | ▶ | $26.88B |
| ROIV Roivant Sciences Ltd. | ▲ | $24.22B |
| GMAB Genmab A/S | ▲ | $23.80B |
| UTHR United Therapeutics Corp | ▶ | $22.87B |
| VTRS Viatris Inc | ▼ | $21.43B |
| INSM Insmed Inc | ▶ | $21.02B |
| ASND Ascendis Pharma A/S | ▲ | $14.85B |
| JAZZ Jazz Pharmaceuticals Plc | ▼ | $13.65B |
| BBIO Bridgebio Pharma, Inc. | ▶ | $12.98B |
| CORT Corcept Therapeutics Inc | ▲ | $11.91B |
| ELAN Elanco Animal Health Inc | ▼ | $11.77B |
| SMMT Summit Therapeutics Inc. | ▶ | $11.67B |
| RDY Dr Reddys Laboratories Ltd | ▼ | $10.91B |
| BMRN Biomarin Pharmaceutical Inc | ▶ | $10.58B |
| MDGL Madrigal Pharmaceuticals, Inc. | ▶ | $10.39B |
| CYTK Cytokinetics Inc | ▲ | $8.61B |
| TGTX Tg Therapeutics, Inc. | ▲ | $8.56B |
| PTGX Protagonist Therapeutics, Inc | ▶ | $8.33B |
| AXSM Axsome Therapeutics, Inc. | ▲ | $8.23B |
| ARWR Arrowhead Pharmaceuticals, Inc. | ▲ | $7.90B |
| ABVX Abivax S.A. | ▼ | $7.74B |
| IONS Ionis Pharmaceuticals Inc | ▲ | $7.14B |
| SYRE Spyre Therapeutics, Inc. | ▲ | $7.05B |
| ALKS Alkermes Plc. | ▲ | $6.92B |
| PRAX Praxis Precision Medicines, Inc. | ▲ | $6.75B |
| KNSA Kiniksa Pharmaceuticals International, Plc | ▶ | $6.13B |
| AMRX Amneal Pharmaceuticals, Inc. | ▲ | $6.13B |
| RYTM Rhythm Pharmaceuticals, Inc. | ▲ | $5.93B |
| LGND Ligand Pharmaceuticals Inc | ▶ | $5.89B |
| BLTE Belite Bio, Inc | ▲ | $5.62B |
| MIRM Mirum Pharmaceuticals, Inc. | ▲ | $5.20B |
| COGT Cogent Biosciences, Inc. | ▶ | $5.12B |
| PTCT Ptc Therapeutics, Inc. | ▲ | $4.94B |
| ORKA Oruka Therapeutics, Inc. | ▲ | $4.76B |
| ERAS Erasca, Inc. | ▲ | $4.68B |
| MANE Veradermics, Inc | ▲ | $4.55B |
| TVTX Travere Therapeutics, Inc. | ▲ | $4.44B |
| EWTX Edgewise Therapeutics, Inc. | ▲ | $4.04B |
| DNTH Dianthus Therapeutics, Inc. /De/ | ▲ | $4.03B |
| INDV Indivior Pharmaceuticals, Inc. | ▶ | $3.83B |
| TNGX Tango Therapeutics, Inc. | ▲ | $3.72B |
Where ALNY sits on the market map
Life Sciences · Pharmaceutical Preparations
News
Alnylam Pharmaceuticals, Inc. (ALNY) stock news
Alnylam Pharmaceuticals, Inc. - Depositary receipt price target increased by 10.26% to R$105.31
The average one-year price target for Alnylam Pharmaceuticals, Inc. - Depositary Receipt (BOVESPA:A1LN34) has been revised to R$105.31 / share. This is an increase of 10.26% from the prior estimate of ...
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Good morning. I'm Tazeen Ahmad. I'm one of the senior biotech analysts at the bank. It's my pleasure to have our next presenting company with us, Alnylam Pharmaceuticals. Sitting up here on stage with ...
FAQ
Alnylam Pharmaceuticals, Inc. (ALNY) stock forecast FAQ
What is the Alnylam Pharmaceuticals, Inc. (ALNY) stock forecast?
On Oct. 16, 2026, ALNY is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5172 stocks scored that day.
How accurate are Alnylam Pharmaceuticals, Inc. stock predictions?
For ALNY, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 56.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 32.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Alnylam Pharmaceuticals, Inc. forecasts updated?
Alnylam Pharmaceuticals, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Alnylam Pharmaceuticals, Inc.'s industry peers?
60 issuers in our coverage, ALNY included, share the SEC industry code Pharmaceutical Preparations. The largest are: Eli Lilly & Co (LLY), Johnson & Johnson (JNJ), Abbvie Inc. (ABBV), Merck & Co., Inc. (MRK), Novartis Ag (NVS), Astrazeneca Plc (AZN).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.